Q2 2025 Ascendis Pharma A/S Earnings Call Transcript
Key Points
- Ascendis Pharma AS (ASND) reported strong revenue growth, with total product revenue reaching EUR153.7 million in Q2 2025, despite currency headwinds.
- YORVIPATH's revenue more than doubled to EUR103 million in Q2, reflecting strong demand and successful market penetration.
- The FDA granted priority review for TransCon CNP, recognizing its potential to significantly improve the treatment of achondroplasia.
- SKYTROFA received FDA approval for adult growth hormone deficiency, expanding its market potential.
- The company is on track to become cash flow positive on a quarterly basis this year, indicating strong financial health and operational efficiency.
- The company faces challenges with currency exchange rates, which negatively impacted revenue by EUR7.6 million in Q2.
- SG&A expenses increased significantly, up 44% year over year, driven by global commercial expansion.
- There is a three-month average delay from patient enrollment to conversion for YORVIPATH, indicating potential inefficiencies in the approval process.
- The company is still in the early stages of the YORVIPATH launch, with uncertainties around long-term patient enrollment trends.
- There is no clear definition of 'severe' hypoparathyroidism, complicating the targeting and treatment of patients.
Good day and thank you for standing by. Welcome to the Q2 2025 Ascendis Pharma earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Scott Smith, Ascendis Pharma Inc CFO. Please go ahead.
/- -
(spoken in foreign language), operator, and thank you, everyone, for joining our second-quarter 2025 financial results conference call. I'm Scott Smith, Executive Vice President and Chief Financial Officer at Ascendis Pharma. Joining me on today's call are Jan Møller Mikkelsen, President and Chief Executive Officer; Sherrie Glass, Chief Business Officer; Jay Wu, Executive Vice President and President, US Market; Aimee Shu, Executive Vice President of Endocrine and Rare Disease Medical Science and Chief Medical Officer.
Before we begin, I would like to remind you that this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
